Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control

Diabetes Care

Volumn 24, Issue 11, 2001, Pages 1957-1960

  Gokcel, Adnan ^a   Karakose, Hatice ^a   Ertorer, Eda Melek ^a   Tanaci, Nedret ^a   Tutuncu, Neslihan Bascil ^a   Guvener, Nilgun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIDIABETIC AGENT; CHOLESTEROL; CYCLOBUTANE DERIVATIVE; GLIPIZIDE; INSULIN; METFORMIN; PLACEBO; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; OBESITY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; BLOOD GLUCOSE; CHOLESTEROL; CYCLOBUTANES; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; OBESITY; PLACEBOS; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 0035512619     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.11.1957     Document Type: Article

References (24)

1. Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 20:1744-1766, 1997
2. Albu J, Konnarides C, Pi-Sunyer X: Weight control: metabolic and cardiovascular effects. Diabetes Rev 3:335-347, 1995
3. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D: Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147:1749-1753, 1987
4. Lean ME, Powrie JK, Anderson AS, Garthwaite PH: Obesity, weight loss and prognosis in type 2 diabetes. Diabetes Med 7:228-233, 1990
5. Close EJ, Wiles PG, Lockton JA, Walmsley D, Oldham J, Wales JK: Diabetic diets and nutritional recommendations: what happens in real life? Diabet Med 9:181-188, 1992
6. Manning RM, Jung RT, Leese GP, Newton RW: The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 12:409-415, 1995
7. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
8. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycemia with macrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
9. Pyörälä K, Pedersen TR, Kjekshus J: The effect of cholesterol lowering with simvastatin on coronary artery diseases in diabetic patients with coronary artery disease (Abstract). Diabetes 44 (Suppl. 1):35A, 1995
10. Willey KA, Molyneaux LM, Yue DK: Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabet Med 11:701-704, 1994
11. O'Kane M, Wiles PG, Wales JK: Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 11:105-110, 1994
12. DaubresseJC, KolanowskiJ, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L: Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 4:391-396, 1996
13. McNeely W, Goa KL: Sibutramine: a review of its contribution to the management of obesity. Drugs 56:1093-1124, 1998
14. Day C, Bailey CJ: Effect of antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 22:619-623, 1998
15. Gokcel A, Gumurdulu Y, Karakose H, Karademir BM, Anarat R: Effects of sibutramine on leptin levels in nondieting obese women (Abstract). Int J Obes Relat Metab Disord 24 (Suppl. 1):S171, 2000
16. Kelley DE: Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 3:366-377, 1995
17. Schneider SH, Morgado A: Effects of fitness and physical training on carbohydrate metabolism and associated cardiovascular risk factors in patients with diabetes. Diabetes Rev 3:378-407, 1995
18. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, Sibutramine/Diabetes Clinical Study Group: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diab Obes Metab 2:175-187, 2000
19. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diab Obes Metab 2:105-112, 2000
20. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
21. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes (Review). Diabetes Care 18:258-268, 1995
22. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73:460-468, 1994
23. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E: Longterm maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106:179-184, 1999
24. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P: Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 22:32-38, 1998